Further Victory For Celltrion and Teva, As Their Trastuzumab Biosimilar, Herzuma, Receives FDA Approval

 
• By Dean Rudge

Less than a month after the FDA greenlit their Truxima (rituximab-abbs) biosimilar, partners Celltrion and Teva are toasting approval for their Herzuma (trastuzumab-pkrb) biosimilar, albeit with a limited set of indications; a date for market entry is also unclear at this stage.

Archery
Bullseye for Celltrion and Teva, as they bag trastuzumab and rituximab approvals in quick succession. • Source: Shutterstock

More from Biosimilars

More from Products